April 3 (Reuters) - Allergan Plc - For Rgh-Md :
* ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM THIRD OF THREE PIVOTAL TRIALS OF CARIPRAZINE IN BIPOLAR I DEPRESSION
* PRIMARY ENDPOINT WAS MET IN STUDY EVALUATING PATIENTS WITH ACUTE BIPOLAR I DEPRESSION TREATED WITH CARIPRAZINE 1.5 MG VERSUS PLACEBO
* PLANS TO INCLUDE DATA FROM ALL THREE PIVOTAL TRIALS IN CO’S SNDA TO U.S. FDA IN SECOND HALF OF 2018
* MOST COMMONLY REPORTED ADVERSE EVENTS IN CARIPRAZINE GROUPS WERE AKATHISIA, RESTLESSNESS, NAUSEA, AND FATIGUE
* EFFICACY OF CARIPRAZINE IN TREATMENT OF BIPOLAR I DEPRESSION HAS BEEN DEMONSTRATED IN THREE POSITIVE PIVOTAL TRIALS
* 53, PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS WERE MET FOR CARIPRAZINE 1.5 MG DOSE GROUP Source text for Eikon: Further company coverage: